Molecure (MOC) Investor Presentation summary

Company overview and leadership

• Molecure is advancing a pipeline of first-in-class, differentiated assets targeting unmet needs in inflammation, fibrosis, and oncology.

• The management team includes expertise in scientific, medical, and financial leadership, with recent appointment of a new Chief Medical Officer.

Pipeline highlights and clinical progress

• OATD-01 is in Phase 2 for pulmonary sarcoidosis, with patient enrolment ongoing and interim analysis planned for mid-2025.

• OATD-01 shows strong translational data and high market potential in MASH, with plans to initiate clinical trials in partnership.

• OATD-02, a dual arginase inhibitor for cancer, is in Phase 1 dose escalation, with no dose-limiting toxicities observed to date.

• Preclinical programs include a USP7 inhibitor (in collaboration with Avicenna Biosciences) and mRNA-targeted therapies for oncology and autoimmune diseases.

OATD-01: Sarcoidosis and MASH opportunity

• The KITE study is a double-blind, placebo-controlled Phase 2 trial in pulmonary sarcoidosis, active across multiple countries with 13+ sites.

• Patient enrolment strategies are tailored by region, leveraging advocacy groups and direct advertising.

• OATD-01 targets CHIT1, a novel mechanism with disease-modifying potential in MASH, Crohn's disease, and other ILDs.

• Market potential: MASH ($25.8B by 2032), Crohn's ($14.7B), sarcoidosis ($1-2B), and other ILDs ($4B by 2029).

• CHIT1 inhibition reduces hepatic inflammation and fibrosis in preclinical MASH models and correlates with disease severity in patients.